DCC-3084 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DCC-3084’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DCC-3084 overview
DCC-3084 are under development for the treatment of lung cancer, pancreatic cancer, melanoma, hematological malignancies and central nervous system diseases. The drug candidates act by targeting RAF proto oncogene serine/threonine protein kinase CRAF and serine/threonine protein kinase BRAF. These are being developed based on switch control kinase inhibitor platform. It is administered through oral route.
Deciphera Pharmaceuticals overview
Deciphera Pharmaceuticals is a research and development company that develops, designs and commercializes kinase-inhibiting drugs. The company provides a clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses a proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals pipeline products include ripretinib, vimseltinib, DCC-3009, DCC-3116 and DCC-3084 treat renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, Crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DCC-3084’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
